Quick Takeaways:
- Jaguar Health completed submission of a New Animal Drug Application (NADA) to the FDA’s Center for Veterinary Medicine seeking full approval of Canalevia-CA1 (crofelemer) for the treatment of chemotherapy-induced diarrhea (CID) in dogs, following its current conditional approval status.
- The application is supported by a pivotal effectiveness study showing that dogs treated with Canalevia-CA1 achieved normal average daily stool consistency after three days, while 77% of owners considered the treatment effective and approximately 40% reported complete resolution of CID, compared with 10.5% among dogs receiving no CID treatment.
- Canalevia-CA1 is a non-antibiotic therapy, addressing a significant unmet need in veterinary oncology where diarrhea is a common chemotherapy-related complication. The submission also includes positive data from a study evaluating crofelemer in dogs receiving the tyrosine kinase inhibitor neratinib, supporting the drug’s potential role in managing cancer therapy-related diarrhea.
Why It Matters?
Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary oncology. A validated, non-antibiotic option for chemotherapy-induced diarrhea could improve prescribing confidence, support broader clinic uptake, and position crofelemer as a differentiated supportive-care therapy if the FDA review is favorable
Source: Access Newswire
